Vistin Pharma ASA VISTN
OSL · Norway · Health Technology
NOK 18.25-0.25 (-1.35%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Vistin Pharma ASA (STU:VP4) navigates a 9% revenue dip with strong 66% gross margins, while advancing its new DC 95% product and securing long-term energy stability.
Oslo, Norway, 20 August 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the second quarter and first half of 2026. Revenue in the second quarter amounted to MNOK 100, compared to MNOK 118 in Q2 2025. Sales volume increased by 8%, offset by a significantly stronger NOK against EUR in the quarter compared to 2025, impacting sales in local currency. Revenue for the first half of 2026 amounted to MNOK 212, compared to MNOK 233 in the corresponding period of 2025, representin
Oslo, Norway, 13 August 2026 Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion. The second quarter conference call will be accessible via web and audio through the following access points: Webcast: https://edge.media-server.com/mmc/p/abe93pzc Telephone
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.